Stock Pulse
STERIS (STE) reported Q4 revenue of $1.37 billion, a 5.6% year-over-year increase, slightly missing analyst expectations and representing weaker performance compared to peers [4], [5], [6]. Despite this, full-year EPS guidance met expectations, and the stock saw a modest increase [6]. A subsidiary, Isomedix, reached a $48.15 million settlement agreement for ethylene oxide emission lawsuits [7]. While the settlement avoids further litigation, it will impact fiscal year 2025 earnings. STERIS faces ongoing risks including public health crises, integration challenges, regulatory changes, and supply chain disruptions [7]. Although the company benefited from a broader market rally [1], analysts have expressed concern over stagnant margins and valuation [2].